Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Daniel Pichl Biography and Net Worth

Chief People Officer of SpringWorks Therapeutics

Daniel Pichl joined SpringWorks Therapeutics in 2020. He has more than 15 years of experience as an accomplished human resource professional. Previously, Daniel was at Siemens Healthineers, USA where he was Senior Vice President, Head of Human Resources and Global HR Business Partner for the Ultrasound division. At Siemens, he had global responsibility for People Strategy, Employee Relations, Compensation & Benefits, Talent Acquisition, Talent & Performance Management, Leadership Development, and Learning. Prior to this role, he served as Vice President, Head of People & Leadership for the Americas region, and before that, he held positions of increasing responsibility at Siemens AG, Germany. Daniel earned a Master of International Business degree from Macquarie University in Sydney, Australia, and a Master of Psychology degree from Ludwig-Maximilians-University in Munich, Germany.

What is Daniel Pichl's net worth?: The estimated net worth of Daniel Pichl is at least $1.61 million as of February 16th, 2024. Mr. Pichl owns 45,212 shares of SpringWorks Therapeutics stock worth more than $1,609,095 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Pichl may own. Additionally, Mr. Pichl receives a salary of $428,510.00 as Chief People Officer at SpringWorks Therapeutics. Learn More about Daniel Pichl's net worth.
How old is Daniel Pichl?: Mr. Pichl is currently 40 years old. There are 7 older executives and no younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics is Mr. Herschel S. Weinstein J.D., General Counsel & Secretary, who is 67 years old. Learn More on Daniel Pichl's age.
What is Daniel Pichl's salary?: As the Chief People Officer of SpringWorks Therapeutics, Inc., Mr. Pichl earns $428,510.00 per year. There are 6 executives that earn more than Mr. Pichl. The highest earning executive at SpringWorks Therapeutics is Mr. Saqib Islam J.D., CEO & Director, who commands a salary of $1,490,000.00 per year. Learn More on Daniel Pichl's salary.
How do I contact Daniel Pichl?: The corporate mailing address for Mr. Pichl and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at [email protected]. Learn More on Daniel Pichl's contact information.
Has Daniel Pichl been buying or selling shares of SpringWorks Therapeutics?: Daniel Pichl has not been actively trading shares of SpringWorks Therapeutics during the past quarter. Most recently, Daniel Pichl sold 15,000 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $50.10, for a transaction totalling $751,500.00. Following the completion of the sale, the insider now directly owns 45,212 shares of the company's stock, valued at $2,265,121.20. Learn More on Daniel Pichl's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 35,000 shares worth more than $1,590,900.00. The most recent insider tranaction occured on December, 3rd when COO Badreddin Edris sold 20,000 shares worth more than $839,400.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 12/3/2024.

Daniel Pichl Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/16/2024	Sell	15,000	$50.10	$751,500.00	45,212
1/26/2023	Sell	858	$31.00	$26,598.00	35,203

Daniel Pichl Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $35.59

$34.56

$35.94

50 Day Range

MA: $35.43

$28.61

$42.55

2 Week Range

Now: $35.59

$28.21

$53.92

Volume

1,260,985 shs

Average Volume

1,008,921 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Daniel Pichl Biography and Net Worth

What is Daniel Pichl's net worth?

How old is Daniel Pichl?

What is Daniel Pichl's salary?

How do I contact Daniel Pichl?

Has Daniel Pichl been buying or selling shares of SpringWorks Therapeutics?

Who are SpringWorks Therapeutics' active insiders?

Are insiders buying or selling shares of SpringWorks Therapeutics?